Overview

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

Status:
RECRUITING

Trial end date:
2026-11-30

Target enrollment:

Participant gender:

Summary

This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Guangdong Provincial People's Hospital

Collaborator:

Guangzhou Virotech Pharmaceutical Co., Ltd.

Treatments:

Drug Therapy